Julie Silber is a strategic and results-driven executive with over 25 years of experience in Investor Relations, Capital Markets, Corporate Strategy, and Board Advisory across North America and Europe, with a strong focus on life sciences, biotech, precision medicine, and diagnostics. She currently serves on the Board of Directors of Orbit Genomics

Julie has led investor relations, corporate governance, and strategic communications for companies navigating growth, transformation, and crisis in innovation-driven sectors, including molecular diagnostics, precision medicine, and life science tools. She has extensive experience supporting the commercialization of diagnostic products and LDTs from CLIA-certified, CAP-accredited laboratories—translating clinical data, regulatory and reimbursement strategy, and go-to-market milestones into clear, credible messaging for investors, clinicians, and health-system partners. As a Board Advisor and former Interim CFO, she has guided executive teams through M&A, investor strategy, and long-term planning, driving outcomes such as increased analyst coverage, market visibility, and investor engagement.

A serial entrepreneur, Julie has founded and scaled several profitable ventures. She brings a sharp ability to translate complex technology and science into accessible language and offers independent perspective, strategic counsel, and boardroom communication expertise to companies developing next-generation diagnostic and life science solutions.

Julie holds a Certificate in Corporate Governance from the Wharton School at the University of Pennsylvania. She earned her undergraduate degree in International Relations from the University of Southern California as well as a multi-disciplinary master’s degree in environmental science & policy.